AbbVie Inc (ABBV)vsArriVent BioPharma, Inc. Common Stock (AVBP)
ABBV
AbbVie Inc
$290.89
+1.68%
HEALTHCARE · Cap: $504.37B
AVBP
ArriVent BioPharma, Inc. Common Stock
$15.95
+1.40%
HEALTHCARE · Cap: $884.58M
Smart Verdict
WallStSmart Research — data-driven comparison
ABBV leads profitability with a 9.8% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
AVBP
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-86.7%
Fair Value
$152.97
Current Price
$290.89
$137.92 premium
Intrinsic value data unavailable for AVBP.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.54 suggests the stock is reasonably priced for its growth.
Bull Case : AVBP
The strongest argument for AVBP centers on Debt/Equity, Altman Z-Score, Price/Book.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 80.6x leaves little room for execution misses.
Bear Case : AVBP
The primary concerns for AVBP are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
AVBP carries more volatility with a beta of 1.35 — expect wider price swings.
ABBV is growing revenue faster at 10.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.1B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (73/100 vs 26/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
ArriVent BioPharma, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
ArriVent BioPharma, Inc. (AVBP) is a dynamic biopharmaceutical company dedicated to developing pioneering therapies that address critical unmet needs in oncology and autoimmune diseases. The company harnesses proprietary technologies and a strong scientific foundation to create a promising pipeline aimed at enhancing patient outcomes. Positioned in high-growth sectors of the biopharma industry, ArriVent presents an appealing investment opportunity for institutional investors looking to engage in impactful healthcare innovations with substantial market potential.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?